Glaxo Wellcome
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Glaxo Wellcome sits in the top decile of US sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count).
Glaxo Wellcome: 65 sponsored US clinical trials, none currently recruiting.
Glaxo Wellcome sponsors 65 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 65 completed. 17 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 18 trials.
Top-decile sponsor footprint
Glaxo Wellcome ranks in the top decile of sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
65 of 65 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
65 total, page 2 of 2
A Study of 1592U89 in HIV-Infected Children
NCT00002197
The Safety and Effectiveness of 524W91
NCT00002335
A Study of 1592U89 in HIV-Infected Adults
NCT00002200
A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications
NCT00002417
A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX
NCT00002340
An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2
NCT00002023
A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.
NCT00002199
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
NCT00002026
The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease
NCT00002001
Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure
NCT00002047
The Effect of Teaching HIV-Infected Patients About HIV and Treatment
NCT00002409
A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex
NCT00002163
The Safety and Effectiveness of 935U83 in HIV-Infected Patients
NCT00002338
A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
NCT00002000
A Comparison of 141W94 and Indinavir in HIV-Infected Patients
NCT00002202
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 10 |
| Phase 3 | 13 |
| Phase 4 | 4 |
Therapeutic Areas
How the Glaxo Wellcome archive is shaped
65 indexed studies, none listed as recruiting (0% open); 65 completed (100%).
Phase mix: 17 late (III/IV) vs 18 early (I/II) (balanced across stages).
Top condition: HIV Infections (18 trials), 5 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Glaxo Wellcome: archived-pipeline peers nationwide
Peers matched on 65 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Glaxo Wellcome sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 65 archived trials
- BeiGene · 65 trials · 14% recruiting
- LEO Pharma · 65 trials · 5% recruiting
- Neurocrine Biosciences · 65 trials · 18% recruiting
- Women and Infants Hospital of Rhode Island · 65 trials · 22% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Glaxo Wellcome page
65 registered trials is a research-attention snapshot, not an endorsement of Glaxo Wellcome or any single study.
- None of Glaxo Wellcome's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- HIV Infections is the condition Glaxo Wellcome studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Glaxo Wellcome pipeline card: 65 registered trials from official public datasets.Report a data error.